Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S.

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
TipRanks on MSN

Novo Nordisk’s New Insulin Study: A Potential Game-Changer for Diabetes Management

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Healio

20 years later, ‘a tremendous amount going on’ in management of cardiometabolic disease

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...
Verywell Health on MSN

More Price Cuts Are Coming for Diabetes Drugs. Here's What to Expect in 2026

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...
The Hospitalist

New Diabetes Medications and Holistic Management

Hospitalized patients with diabetes require specialized management to reduce readmission rates and complications. Newer ...
Clinical Advisor

FDA to Ease Copycat Drug Rules, Speeding Access to Cheaper Drugs

Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...